Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $215M
Founded date: 2020
Investors 4
Date | Name | Website |
- | Vida Ventu... | vidaventur... |
- | Atlas Vent... | atlasventu... |
- | NFLS - Piv... | pivotalbio... |
20.08.2021 | Lightstone... | lightstone... |
Funding Rounds 3
Date | Series | Amount | Investors |
16.08.2022 | - | $75M | - |
18.08.2021 | Series B | $90M | - |
17.12.2020 | Series A | $50M | - |
Mentions in press and media 5
Date | Title | Description | Source |
16.08.2022 | Vigil Neuroscience Announces $75 Million Private Placement F... | - | lightstone... |
12.08.2022 | Vigil Neuroscience Announces $75 Million Private Placement F... | CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clini... | globenewsw... |
18.08.2021 | Vigil Neuroscience Completes $90M Series B | CAMBRIDGE, MA, Vigil Neuroscience, a biotechnology company announced the completion of a $90 milli... | vcnewsdail... |
08.12.2020 | Vigil Neuroscience Launches $50 Million Series A | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vigil Neuroscience, a new biotechnology company harnessing the po... | citybizlis... |
08.12.2020 | Neurodegeneration startup launches with $50M, Amgen assets | Eight years after Atlas Venture began probing a group of nervous system cells and their effects in A... | bizjournal... |